Trial Profile
Safety and Efficacy of Apixaban in Severe Renal Impairment
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 25 Aug 2022 Planned End Date changed from 10 Jul 2019 to 24 Aug 2022.
- 07 Jul 2019 Planned primary completion date changed from 10 May 2019 to 7 Jul 2019.
- 22 Jan 2018 New trial record